Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistance

Abstract Lenvatinib is the first target drug approved for advanced hepatocellular carcinoma (HCC). However, the development of drug resistance is common, and the mechanisms of lenvatinib resistance and resistant targets in HCC are poorly understood. By using CRISPR/Cas9 library screening, we screene...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yonggang Lu, Haoming Shen, Wenjie Huang, Sha He, Jianlin Chen, Di Zhang, Yongqi Shen, Yifan Sun
Formato: article
Lenguaje:EN
Publicado: Nature Publishing Group 2021
Materias:
Acceso en línea:https://doaj.org/article/3fda2f305bd648cd807dee2f0ef61d95
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!